John A. Jakob, Roland L. Bassett Jr., Chaan S. Ng, Jonathan L. Curry, Richard W. Joseph, Gladys C. Alvarado, Michelle L. Rohlfs, Jessie Richard, Jeffrey E. Gershenwald, Kevin B. Kim, Alexander J. Lazar, Patrick Hwu and Michael A. Davies NRAS mutation status is an independent prognostic factor in metastatic melanoma Cancer 118
Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26724
Patients who have metastatic melanoma with mutations of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) or neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) genes are more likely than those with the wild-type of both genes to have central nervous system involvement at the diagnosis of distant metastases. NRAS mutation status is an independent predictor of shorter survival after the diagnosis of stage IV melanoma.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field